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Abstract
Over the past three decades, antimicrobial resistance in Streptococcus pneumoniae has dramatically increased worldwide. Non-susceptibil-
ity to penicillin in S. pneumoniae was first described in Australia in 1967, and later in New Guinea (1974), South Africa (1977), and Spain
(1979). Most of these strains showed resistance to multiple antibiotics and belonged to serotypes 6A, 6B, 19A, 19F, and 23F. By the late
1980s and 1990s, the emergence and rapid dissemination of antibiotic-resistant pneumococci was observed in southern and eastern Eur-
ope, North America, South America, Africa, and Asia. Great geographical variability, both in serotype distribution and in the prevalence
of resistant pneumococci, has been reported. However, the highest rates of resistance to penicillin and erythromycin worldwide were
found in serotypes 6B, 6A, 9V, 14, 15A, 19F, 19A, and 23F. The introduction of the seven-valent pneumococcal conjugate vaccine
(PCV7) in the 2000s and a reduction in antimicrobial use were associated with a significant decline in the incidence of invasive pneumo-
coccal infections and in rates of antibiotic resistance in the USA. However, an increase in the incidence of infections caused by non-
PCV7 serotypes, especially multiresistant serotype 19A pneumococci, has been observed in many countries over the last 5 years. The
dynamic character of serotypes and antibiotic resistance in S. pneumoniae should be controlled by a policy of prudent antibiotic use and
by implementation of the new generation of conjugate vaccines.
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Introduction
Streptococcus pneumoniae is the most important pathogen in
otitis, sinusitis, bronchitis, and community-acquired pneumo-
nia, as well as a predominant cause of meningitis and bacter-
aemia. Before 1967, this pathogen was uniformly susceptible
to penicillin and most other antimicrobial agents. The first
penicillin-non-susceptible pneumococcus was described in
Australia in 1967; it had an MIC of penicillin of 0.6 mg/L, and
it also showed resistance to tetracycline (MIC 5 mg/L) [1].
In 1974, 12% of 518 New Guinean isolates were penicillin-
non-susceptible pneumococci (PNSP) [2]. Pneumococci with
much higher resistance to penicillin and other antibiotics
were first detected in 1977 in South Africa [3,4]. These
multidrug-resistant pneumococci of serotypes 6A and 19A
had penicillin MICs ranging from 0.12 to 4 mg/L, and were
isolated from hospitalized paediatric carriers (29% of 543),
causing bacteraemia in four patients [4]. In Spain, the first
PNSP strain with a penicillin MIC of 0.5 mg/L was isolated
from the blood from an adult patient in a hospital in Barce-
lona in 1979, and a year later one invasive isolate with a pen-
icillin MIC of 2 mg/L was detected in the same hospital in
Barcelona [5]. By the 1980s, a high prevalence of antibiotic
resistance among pneumococci was being reported in other
countries, leading to serious therapeutic problems, mainly in
the treatment of pneumococcal meningitis [3,4,6–10]. The
emergence and rapid dissemination of antibiotic-resistant
pneumococcal clones in areas of southern and eastern Eur-
ope, North America, South America and Asia in the 1990s
was associated with an increase in antibiotic consumption
[11,12].
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Although 92 pneumococcal serotypes have been
described, the highest penicillin and erythromycin resistance
proportions worldwide were associated with serotypes 6B,
6A, 9V, 14, 15A, 19F, 19A, and 23F, the so-called ‘paediatric
serotypes’. The introduction of the seven-valent pneumococ-
cal conjugate vaccine (PCV7) for children in the 2000s, which
included serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, was
associated with a significant decline in penicillin resistance
rates in S. pneumoniae in many countries [13–16]. However,
an increase in the incidence of non-PCV7 serotypes, espe-
cially multiresistant serotype 19A strains, has been observed
in many countries over the last 5 years [16–22].
This review analyses geographical trends in antibiotic
resistance and the serotypes/genotypes in S. pneumoniae over
the last three decades. It also includes the evolution of peni-
cillin, erythromycin and fluoroquinolone resistance among
invasive pneumococci received at the Spanish Reference Lab-
oratory for Pneumococci over a 30-year period (1979–
2008).
Resistance to b-Lactam Antibiotics
The mechanism of penicillin resistance in S. pneumoniae
involves structural changes in the penicillin targets, the peni-
cillin-binding proteins 1A, 2X, and 2B [23]. These changes
result in reduced affinity for penicillin as well as for other b-
lactam antibiotics. However, ceftriaxone, cefotaxime and car-
bapenems are less affected, and are generally the most active
compounds [24].
Previous studies have demonstrated that PNSP
(MICs ‡0.12 mg/L) can be associated with treatment failures
in patients with meningitis, because the cerebrospinal fluid
levels achieved with penicillin or the standard dosage of
third-generation cephalosporins are insufficient to eradicate
the infecting organism. The classical NCCLS breakpoints for
penicillin (susceptible, £0.06 mg/L; intermediate, 0.12–1 mg/L;
and resistant, ‡2 mg/L) were established in the late 1970s in
order to prevent failures in patients with pneumococcal
meningitis caused by PNSP. In contrast, S. pneumoniae strains
with penicillin MICs of 0.12–2 mg/L had little effect on out-
come in patients with pneumonia and other non-meningeal
systemic pneumococcal infections who were treated with
parenteral penicillin, amoxycillin, cefotaxime, or ceftriaxone
[25–31]. According to these observations, the CLSI break-
points for ceftriaxone and cefotaxime were modified in
2002, distinguishing between meningeal infections (suscepti-
ble, MIC £0.5 mg/L; intermediate, MIC 1 mg/L; and resistant,
MIC ‡2 mg/L) and non-meningeal infections (susceptible,
MIC £1 mg/L; intermediate, MIC 2 mg/L; and resistant,
MIC ‡4 mg/L). However, penicillin breakpoints were not
modified until 2008, when the site of infection and route of
administration were considered. The current penicillin paren-
teral breakpoints for non-meningeal infections are
MIC £2 mg/mL (susceptible), MIC 4 mg/mL (intermediate),
and MIC ‡8 mg/mL (resistant), whereas MICs ‡0.12 mg/L for
strains causing meningeal infection are considered to reflect
resistance [32].
In the USA, S. pneumoniae was uniformly susceptible to
penicillin until 1987. After that, rates of PNSP with a penicil-
lin MIC ‡0.1 mg/L progressively increased from very low
rates (5%) before 1991 to 14% in 1993–1994 [33,34]. In
1997, among 3237 invasive isolates, 25% were PNSP, and
among these, 13.6% had a penicillin MIC ‡2 mg/L [35].
Global surveillance studies have shown that b-lactam-non-
susceptibility rates increased worldwide during the 1990s
and 2000s. The Alexander Project monitored resistance in
S. pneumoniae from 1992 to 2001, and reported increases in
the levels of non-susceptibility to penicillin from 24.9% in
1992 to 30.2% in 2001 in Spain, from 7.7% to 35.8% in
France, and from 5.6% to 20.4% in the USA, whereas in Italy,
Germany, and the UK, resistance rates remained below 5%
during this period [36].
The PROTEKT US study, with 39 495 pneumococcal
isolates from patients with community-acquired respiratory
tract infections in the USA, showed that intermediate
non-susceptibility to penicillin (MIC 0.12–1 mg/L) increased
from 12.5% in 2000–2001 to 20.0% in 2003–2004, whereas pen-
icillin resistance (MIC ‡2 mg/L) declined from 26.3% in 2000–
2001 to 16.5% in 2003–2004. However, the percentage of resis-
tance to amoxycillin (MIC ‡8 mg/L) remained low and stable,
from 4.4% in 2000–2001 to 4.1% in 2003–2004 [37]. The PRO-
TEKT study also analysed the antibiotic susceptibility of 20 142
pneumococcal isolates collected worldwide from respiratory
tract infections in 2001–2004. The highest penicillin-non-sus-
ceptiblity rates were found in South Africa (74%), the Far East
(63%), and the Middle East (54%). In southern European coun-
tries, rates of PNSP were higher than those found in northern
European countries. The highest rates of PNSP (intermediate
and resistant isolates) were found in France (40.4% and 15.9%),
Greece (42.0% and 15.9%), and Spain (29.4% and 13.1%) [38]. In
seven Latin American countries, a study of 1561 pneumococcal
isolates collected from 1997 to 2001 revealed a global rate of
PNSP of 30.7%, ranging from 25% in Mexico to 2.8% in Venezu-
ela. Resistance to penicillin (MIC ‡2 mg/L) and cefotaxime
(MIC ‡4 mg/L) was found in 11.9% and 0.4% of isolates, respec-
tively [39]. Southern and eastern countries of the Mediterra-
nean region reported that 26% (335) of the 1298 invasive
isolates studied were PNSP, with the highest proportions being
reported in Algeria (44%) and Lebanon (40%) [40].
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The European Antimicrobial Resistance Surveillance Sys-
tem (EARSS), an international network of national surveil-
lance systems that has been collecting antimicrobial
susceptibility testing data on invasive S. pneumoniae isolates
since 1999, also reported that most northern European
countries had levels of PNSP below 5%, whereas southern
and eastern European countries had PNSP levels above 25%
[41]. In 2008, 1152 (10%) of the 11 584 invasive S. pneumo-
niae isolates reported to the EARSS by 32 countries were
PNSP [41]. Among the northern European countries, only in
Finland and Ireland had the frequency of PNSP risen signifi-
cantly from 2005 to 2008 (7% (37/525) vs. 11% (71/642), and
11% (43/397) vs. 23% (101/441), respectively). In contrast,
four countries with the highest levels of PNSP in the early
2000s (France, Spain, Belgium, and Israel) showed significantly
decreasing rates of PNSP over the subsequent years.
Data from the Spanish Reference Laboratory for Pneumo-
cocci are shown in Fig. 1. A total of 25 166 invasive pneumo-
cocci were received during the period 1979–2008. Rates of
invasive PNSP isolates progressively increased from 6% in
1979 to 44.4% in 1989 (p <0.001), and the proportion of
resistant isolates (MIC ‡2 mg/L) increased from 0% to 15.4%
during this period (p <0.001). During the period 1990–1998,
the proportion of PNSP plateaued, oscillating between 34.5%
and 43.7%. In the last decade, rates of PNSP progressively
decreased from 33.9% in 1999 to 22.3% in 2008 (p <0.001).
This decline was especially marked in 2005–2008, and was
associated with the implementation of PCV7 for children
(Table 1). Moreover, among 1397 pneumococcal isolates
from cerebrospinal fluid, non-susceptibility rates for cefotax-
ime (MIC ‡1 mg/L) decreased from 21.7% in 2000 to 10.5%
in 2008 [16].
In a study performed in 33 US medical centres, the rate
of ceftriaxone non-susceptibility (MIC ‡2 mg/L) decreased
from 14.4% among 1531 pneumococcal isolates collected in
1999–2000 to 5.9% among 1647 pneumococcal isolates col-
lected in 2004–2005 in 41 medical centres [42,43].
In spite of these alarming penicillin resistance levels, pneu-
mococci with penicillin or cefotaxime/ceftriaxone
MICs ‡4 mg/L are rarely described worldwide. If the revised
CLSI breakpoints for parenteral penicillin are applied to
pneumococci isolated from non-meningeal infections, more
than 95% of invasive pneumococcal isolates collected word-
wide are currently susceptible to penicillin and third-genera-
tion cephalosporins [32]. These antibiotics should continue
to be first-line therapy for these infections [25–27,31].
Macrolides
The most frequently encountered mechanism of macrolide
resistance in pneumococci is target site modification medi-
ated by the ermB-encoded methylase, conferring resistance
to all macrolides, lincosamides, and streptogramin B
(MLSB phenotype). The expression of this phenotype can be
constitutive or inducible, becoming active only in the pres-
ence of inducing macrolides. The ermB gene is the major
cause of macrolide resistance in most European countries,
40
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FIG. 1. Trends in penicillin and erythromycin resistance among 19 266 invasive pneumococcal isolates in patients of all ages in Spain (1979–
2008). Ery-R, erythromycin resistance; PCV7, seven-valent pneumococcal conjugate vaccine.
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especially Belgium, France, Poland, Italy, and Spain [38]. The
second most common mechanism is mediated by an efflux
pump codified by the mef genes (mefA, mefE). This mecha-
nism confers the M phenotype, with resistance to 14-mem-
bered and 15-membered ring macrolides, but not to
lincosamides or streptogramins. The M phenotype isolates
predominate in the USA, Canada, the UK, Germany, and
Norway. Less common macrolide resistance could be due to
mutations in the 23S rRNA and/or alterations in ribosomal
proteins (L4 and L22).
The prevalence of macrolide resistance mechanisms differs
considerably among countries, as shown in Table 2 [44–58].
The emergence of pneumococci that carry both ermB and
mefE macrolide resistance genes is a cause for concern,
especially in Asian countries, Russia, South Africa, and the
USA [52,59]. Both genes (ermB and mefE), as well as the tet-
racycline resistance determinant (tetM), have been related to
the composite element Tn2010, which is present in most
multidrug-resistant isolates of serotype 19A of clonal com-
plex 320 [18,60].
Macrolide-resistant pneumococci were first detected in
1967 in Canada, but rates of macrolide resistance among
pneumococci remained low worldwide (<5%) during the
1970s [3]. By the early 1980s, the highest prevalence of
erythromycin-resistant pneumococci was found among pneu-
mococci isolated from hospital carriers in South Africa
(63%), whereas, among invasive isolates, the prevalence of
resistance was 8.3% in 1983. The majority of these strains
showed multidrug resistance [3]. In France, macrolide resis-
tance rates dramatically increased from 0% before 1976 to a
peak of 26% in 1985 among clinical isolates at two hospitals
in Paris [61]. In Spain, resistance rates increased from 0% in
1979–1980 to 9.4% in 1990 in a Barcelona hospital [9].
Thereafter, a rapid worldwide increase in the prevalence of
macrolide resistance associated with an increase in macrolide
consumption, especially of long-acting macrolides such as
clarithromycin and azithromycin, was observed [38,62–64].
Global surveillance studies have shown that macrolide
resistance rates increased during the 1990s. The Alexander
Project gave a global rate of macrolide resistance of 16.5–
21.9% in 1996–1997, increasing up to 24.6% in 1998–2000
[36]. The PROTEKT study showed an overall rate of 31.0%
in 1999–2000, increasing to 37.2% in 2003–2004, but there
was marked geographical variability [37]. The highest rates
(80%) were recorded among isolates collected in the Far
East, followed by South Africa (54%) and southern Europe
(37%), whereas resistance was lowest in Latin America
(15%), Australia (18%), and northern Europe (18%). Macro-
lide resistance in Europe was notably high in isolates col-
lected from Belgium (31.5%), Spain (33.5%), Hungary (39.4%),
Italy (40.8%), Greece (51.4%), and France (55.6%).
The EARSS report for 2008 shows high variability in the
proportion of macrolide resistance in Europe. Whereas
northern European countries, the Czech Republic and Bul-
garia reported resistance rates below 5%, Italy, Turkey,
France, Hungary and Cyprus reported resistance rates above
25% [41].
In Spain, overall macrolide resistance rates among invasive
pneumococci received at the Spanish Reference Laboratory
for Pneumococci remained below 5% until 1986, but thereafter
TABLE 1. Trends in antibiotic resistance of 19 266 invasive pneumococcal isolates (all ages) tested at the Spanish Reference
Laboratory for Pneumococci according to the old and the new breakpoints for penicillin of the CLSI
Antibiotic breakpoints
Proportions of isolates resistant to antibiotics at indicated MIC breakpoints (%)
Patients
p-value
(1997
vs. 2008)1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Old breakpoints
Penicillin-intermediate MIC of 0.12–1 mg/L 30.0 26.2 22.9 19.8 21.3 23.5 21.0 19.5 16.1 18.2 15.3 16.3 Adults <0.001
36.4 42.2 39.6 39.0 36.0 34.1 33.3 28.6 22.5 20.8 19.2 21.8 Childrena <0.001
Penicillin-resistant MIC of >2 mg/L 11.6 9.7 9.1 9.4 7.6 7.0 6.1 7.8 6.9 4.1 6.2 4.8 Adults <0.001
11.1 11.6 8.9 12.4 13.9 11.0 5.3 9.7 6.7 5.0 7.2 5.6 Children 0.03
New penicillin parenteral breakpoints (non-meningitis)
Penicillin-intermediate MIC of 4 mg/L 0.6 0.1 0 0.3 0.7 0.4 0.4 1.0 0.7 0.1 0.7 0.4 Adults 0.54
0.6 0 0 0 1.9 0.6 0.8 1.0 1.4 0.2 1.8 0.2 Children 0.42
Penicillin-resistant MIC of >8 mg/L 0 0 0 0 0 0 0 0 0 0 0 0 Adults and children
New penicillin parenteral breakpoints (meningitis)
Penicillin-resistant MIC of >0.12 mg/L 41.5 35.9 32.1 29.2 28.9 30.4 27.0 27.3 23.1 22.3 21.5 21.1 Adults <0.001
47.5 53.8 48.4 51.4 49.8 45.1 38.7 38.3 29.2 25.8 26.4 27.4 Children <0.001
Erythromycin-resistant MIC of >1 mg/L 22.7 21.8 21.9 20.4 24.0 23.6 22.9 25.2 20.7 20.8 21.5 20.7 Adults 0.24
32.1 39.3 39.6 39.5 42.7 35.3 42.9 34.4 30.0 20.8 22.3 26.6 Children 0.001b
Dual resistance 18.9 18.1 16.8 14.1 15.2 15.6 13.9 15.4 11.0 11.6 12.3 11.5 Adults <0.001
26.5 35.3 26.6 31.0 33.3 24.3 25.1 20.4 16.7 12.5 14.2 18.1 Children 0.02
Total
IPD episodes (adults) 721 729 1129 1013 914 1107 1140 1132 1513 1454 2039 2188 15 079
IPD episodes (children) 162 173 192 210 267 317 375 392 510 457 613 519 4187
IPD, invasive pneumococcal disease.
aChildren: <14 years old.
bp <0.001 when comparing 1997–2004 vs. 2005–2008.
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increased to 28% in 2001 and decreased to 21.8% in 2008, as
shown in Fig. 1 [16]. After the introduction of PCV7 for chil-
dren in June 2001 in Spain, a significant decline in macrolide
resistance among invasive paediatric isolates (42.9% in 2003 vs.
20.8% in 2006, p <0.001) was observed (Table 1), in agree-
ment with previous reports [13,64]. In contrast, erythromycin
resistance rates among invasive pneumococci isolated from
adult patients remained stable from 1997 to 2008, fluctuating
from 21% to 25% (Table 1) [16].
Several studies have associated macrolide resistance with
therapy failure [65]. This argues against the empirical use of
macrolides for treatment of pneumococcal pneumonia in
countries with high rates of macrolide-resistant pneumococci.
Dual Non-susceptibility to Penicillin and
Erythromycin
Over the 1990s, an increase in the proportion of pneumo-
coccal isolates with combined non-susceptibility to penicillin
and erythromycin was observed. This increase was related
to the spread of classic penicillin-resistant clones that have
acquired determinants of macrolide resistance, mostly car-
ried by transposons of the Tn916 family [51,66]. Data from
the Alexander Project revealed a dramatic increase in the
prevalence of combined resistance from 1.8% in 1992 to
32.7% in 2001 in France, from 3.7% to 17.0% in Spain, and
from 3.2% to 15.3% in the USA [36].
The last EARSS report noted that the overall rate of dual
non-susceptibility remained below 5% in 2008 in Europe.
Although the northern European countries reported the
lowest dual non-susceptibility levels, a decrease in the level
of dual non-susceptibility from 2005 to 2008 was observed
in Belgium (9% vs. 6%) and France (32% vs. 25%). Of concern
is the increase observed over the last 4 years in the level of
dual non-susceptibility in Ireland (from 3% to 12%), Hungary
(from 13% to 21%), and Turkey (from 10% to 23%) [41].
As Table 1 shows, in Spain the rate of combined penicillin
and erythromycin resistance among paediatric isolates fluctu-
ated between 24% and 35% in 1997–2003, and thereafter
showed a significant and progressive decline until it reached
11.5% in 2008 (p <0.05). Among adult isolates, the rate of
combined resistance also declined progressively, from 18.9%
in 1997 to 11.5% in 2008 (p <0.05) [16].
Quinolones
The main mechanism of resistance to fluoroquinolones in
S. pneumoniae is point mutation producing amino acidT
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changes in the quinolone resistance-determining regions of
the subunits of DNA topoisomerase IV (ParC2ParE2) and
DNA gyrase (GyrA2GyrB2). However, resistance can also be
acquired by intraspecific recombination or by interspecific
recombination with streptococci of the mitis group [67–69].
The new, or respiratory, fluoroquinolones such as levo-
floxacin and moxifloxacin have enhanced activity against
pneumococci when compared with the older ones (cipro-
floxacin), and have become therapeutic alternatives for the
treatment of community-acquired pneumonia in adults,
because their spectrum of activity includes S. pneumoniae,
Legionella pneumophila, and other atypical pathogens.
Increased use of these antimicrobials has been associated
with the emergence of resistance in S. pneumoniae in both
Canada and Spain [70,71].
A multicentre study performed in Europe in 2004–2005
involving community-acquired respiratory tract infections
[72] showed a low level of quinolone resistance in the
majority of European countries, with the exception of Poland
(4.4%), Finland (6.6%), and Italy (7.2%). Higher rates were
also detected in some Asian countries [73], as well as
recently in Canada (7.3% in 2006) [74]. In this country, the
increase in ciprofloxacin resistance observed between 1998
(0.6%) and 2006 (7.3%) was strongly associated with an
increase in fluoroquinolone consumption [74]. In Spain, two
nationwide surveillance studies performed in 2002 and 2006
showed a stable rate of ciprofloxacin resistance (2.6% and
2.3%, respectively) [68,69].
There are several reports of treatment failure with the
use of quinolones in the treatment of pneumococcal infec-
tion caused by fluoroquinolone-non-susceptible isolates. The
risk factors identified in these reports were previous fluor-
oquinolone use, chronic obstructive pulmonary disease, hos-
pitalization, and living in nursing homes [73]. However,
once patients with these risk factors were excluded, the
efficacy of levofloxacin in the treatment of pneumococcal
pneumonia was proven [75]. To avoid therapeutic failures,
it is very important to detect strains with first-step muta-
tions, which usually have low-level ciprofloxacin resistance,
with MICs of 4–8 mg/L, and frequently appear to be levo-
floxacin-susceptible, with MICs of 1–2 mg/L [68,69]. These
strains could become highly resistant under selective fluor-
oquinolone pressure. In our experience, the ciprofloxacin
breakpoint of 4 lg/mL, suggested by Chen et al., is the best
marker for detecting strains with first-step mutations [68–
70]. These strains, wrongly identified as susceptible,
accounted for 2.1% of 665 pneumococcal isolates collected
in 2003 during the Canadian Respiratory Organism Suscepti-
bility Study [76].
Antibiotic Resistance and Serotypes/
Genotypes
The worldwide increase in antibiotic resistance in S. pneumo-
niae has been related to the spread of several pneumococcal
serotypes (6A, 6B, 9V, 14, 15A, 19F, 19A, and 23F), the so-
called ‘paediatric serotypes’. In the USA, the CDC’s Active
Bacterial Core surveillance reported that 24% of 3475 inva-
sive pneumococcal isolates collected in 1998 were PNSP.
Seven serotypes (6A, 6B, 9V, 14, 19A, 19F, and 23F)
accounted for 91% of all PNSP [64]. After the introduction
of PCV7 in 2000 in the USA, a dramatic fall in the incidence
of invasive pneumococcal disease (IPD) was observed in chil-
dren £5 years of age and adults ‡65 years of age, associated
with a decrease in IPD caused by PCV7 serotypes [13,14].
However, an increase in IPD caused by non-PCV7 sero-
type 19A was observed in all age groups: from 2.6% in
1998–1999 to 47.2% in 2006–2007 in children £5 years of
age; from 2.9% to 16.6% in adults 18–64 years of age; and
from 3.7% to 14.9% in adults ‡65 years of age [14].
In Spain, an increase in the prevalence of combined peni-
cillin and erythromycin resistance among invasive pneumo-
cocci was associated with antibiotic consumption in the
1980s and 1990s [16]. Data from the Spanish Reference Lab-
oratory for Pneumococci demonstrated that this increase
was related to the rise in prevalence of PCV7 serotypes 6B,
9V, 14, 19F, and 23F, accounting for 76.6% of PNSP in 1979–
1985 and 88% of PNSP in 1998–2000 [16]. The high preva-
lence of penicillin resistance (36.1%) observed among 5697
invasive pneumococcal isolates collected in Spain in the pre-
PCV7 period (1997–2001) was reversed to 22.4% in 2007–
2008 (n = 5465) (p <0.001), when the PCV7 dose distribu-
tion increased. On comparison of these two periods, the
proportions of four serotypes significantly decreased
(p <0.001) among penicillin-resistant strains—serotypes 6B
(16.7% vs. 0%), 9V (15.4% vs. 9.1%), 19F (13.7% vs. 7.3%),
and 23F (12.6% vs. 3.8%)—whereas the proportion of sero-
type 14 was similar in both periods (29.6–26.4%). The pro-
portion of non-PCV7 serotypes among PNSP increased from
12.0% in 1997–2001 to 49.5% in 2007–2008, owing to, in
particular, significant increases in the proportions of sero-
types 19A (3.3–24.5%) and 24F (0.1–7.6%) [16].
The drug-resistant serotypes belong to a small number of
pneumococcal clones whose nomenclature is standardized by
the Pneumococcal Molecular Epidemiology Network (http://
www.sph.emory.edu/PMEN/) [77]. The most important pneu-
mococcal clones involved in the global spread of antibiotic
resistance in the 1980s and 1990s were Spain23F-ST81,
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Spain6B-ST90, Spain9V-ST156, England14-ST9, Taiwan19F-
ST236, Taiwan23F-ST242, Poland6B-ST315, Sweden15A-ST63,
and Colombia23F-ST338. Although Spain23F-ST81 and Spain6B-
ST90 were well-established clones in the 1980s and 1990s,
their prevalence decreased after the introduction of PCV7
[78,79]. Spain9V-ST156 (serotypes 9V and 14) has been an
important cause of IPD in many countries, before and after
PCV7 introduction, and usually shows resistance to penicillin
and co-trimoxazole [15,78,79]. The prevalence of England14-
ST9, associated with the spread of macrolide resistance
(mefA) in the 1990s in the USA, Canada, the UK, Germany,
Norway, Greece, and Italy, decreased significantly after the
introduction of PCV7 [44,48,80,81]. The high rate of penicil-
lin and macrolide resistance detected in Asia and the USA
was partially related to the spread of Taiwan19F-ST236
[55,82]. The increasing prevalence of the multidrug-resistant
serotype 19A observed in the USA is due to the spread of
CC320, a double-locus variant of Taiwan19F-ST236 [17]. This
serotype 19A clone has also been reported in Asia and
Europe [18,19]. However, in Europe, the major clone of
serotype 19A is ST276, related to Denmark14-ST230 [18,20–
22,78].
Antimicrobial use and Antimicrobial
Resistance
The occurrence of drug-resistant pneumococci has been
associated with a variety of factors, antibiotic consumption
being one of the most important [25]. Resistance selection
has mainly occurred in pneumococci colonizing or infecting
children. The frequency of children as carriers, and their
exposure to antibiotics, favours the selection of drug-resis-
tant strains [3,4].
Several studies have shown geographical differences in the
prevalence of antimicrobial resistance in Europe, with lower
rates in the northern countries than in the southern coun-
tries [41]. Outpatient antibiotic consumption in the USA was
recently compared with data from the European Surveillance
Antimicrobial Consumption. Northern European countries
reported the lowest antibiotic use, and southern European
countries (Greece, France and Italy) the highest, similar to
that of the USA. The Netherlands was the country with the
lowest reported consumption [12].
Conclusions
S. pneumoniae continues to be an important cause of invasive
diseases, especially in children and the elderly. The high
prevalence of multiresistant pneumococci in the 1980s and
1990s declined after the introduction of the PCV7 in the
2000s. However, the emergence of drug-resistant non-PCV7
serotypes/genotypes in the late 2000s emphasizes the impor-
tance of prudent use of antibiotics with the aim of preventing
their spread. Continued surveillance of antimicrobial resis-
tance, serotypes and genotypes is crucial in providing infor-
mation on the emergence of multiresistant clones. These
data are also essential for the development of appropriate
guidelines for empirical therapy of pneumococcal infections
and for the inclusion of emergent serotypes in the new
generation of conjugate vaccines.
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